Full details, including potential risk factors, are given in the Press Release, which can be consulted by clicking on the link below
Nicox’s Partner Secures Additional Approval of VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan

March 9, 2020

View Press Release Corporate presentation Contact us
Previous